, A. Pailhé. Clinical Centres
, APHP Pitié-Salpétrière
, APHP Pitié-Salpétrière
Marseille (Service d'Immuno-Hématologie Clinique ,
, Paris (Maladies Infectieuses et Tropicales: G. Pialoux
,
, Toulouse (Maladies Infectieuses et Tropicales: B. Marchou; Hépato-gastro-entérolo-gie: L. Alric, K. Barange, S. Metivier; Anatomo-pathologie, Virologie: F. Larroquette
, Infectiologie: A. Naqvi, V. Rio; Anatomopathologie, Virologie: C. Partouche)
, Médecine Interne-Unité VIH: O. Bouchaud; Anatomo-pathologie: M. Ziol; Virologie: Y. Baazia)
,
, Virologie: F. Nicot
, Virologie: G. Alexandre
,
, P. Bertheau
, Maladies Infectieuses et Tropicales
,
, Virologie: C. Pallier; Maladies Infectieuses: D. Vittecoq
, Virologie: V. Avettand-Fenoel, A. Mélard
, Virologie: P. Trimoulet, S. Reigadas
, Médecine Interne et Maladies Infectieuses: Médecine Interne et Maladies Infectieuses: P. Morlat
, Virologie: P. Trimoulet, S. Reigadas
,
,
,
,
, Virologie: A. Rodallec
, Lyon (Maladies Infectieuses et Tropicales: P
,
,
,
, Maladies infectieuses et tropicales: H. Aumaître)
Reims (Médecine interne, maladies infectieuses et immunologie clinique ,
,
,
, Management
, , 2018.
Expert opinion on the treatment of patients with chronic hepatitis C, J Viral Hepat, vol.16, p.18761607, 2009. ,
Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C, Am Fam Physician, vol.72, p.16127955, 2005. ,
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice, Aliment Pharmacol Ther, vol.23, p.16422999, 2006. ,
Hepatitis C treatment: the data flood goes on-an update from the liver meeting, Gastroenterology, vol.148, p.25576860, 2014. ,
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection, N Engl J Med, vol.370, p.24428467, 2014. ,
All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort, Clin Infect Dis, vol.63, p.27317796, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01993207
Efficacy and safety of directacting antiviral regimens in HIV/HCV-co-infected patients-French ANRS CO13 HEPAVIH cohort, J Hepatol ,
The Hepatitis C Cascade of Care among HIV Infected Patients: A Call to Address Ongoing Barriers to Care, PLoS ONE, vol.9, 2014. ,
Prioritization of high-cost new drugs for HCV: making sustainability ethical, Eur Rev Med Pharmacol Sci, vol.20, p.27049255, 2016. ,
Hépatite C: des traitements très efficaces mais qui profitent à très peu, 2016. ,
Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection, Patient Prefer Adherence, vol.6, p.22536063, 2012. ,
, Discours de Marisol Touraine-Journée de lutte contre les hépatites virales
, , 2016.
Prise en charge thérapeutique et suivi de l'ensemble des personnes infectées par le virus de l'hépatite C. RAPPORT DE RECOMMANDATIONS, p.108, 2016. ,
How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.62, pp.919-945, 2016. ,
Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care, World J Gastroenterol WJG, vol.19, p.24307778, 2013. ,
La co-infection par le virus de l'hépatite C chez les personnes infectées par le VIH: données de l'enquête ANRS-Vespa2, Bull Epidé-miologique Hebd, pp.314-334, 2013. ,
Engaging HIV-HCV coinfected patients in HCV treatment: the roles played by the prescribing physician and patients' beliefs (ANRS CO13 HEPAVIH cohort, France), BMC Health Serv Res, vol.12, p.22409788, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00687514
Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention, PLOS ONE, vol.9, p.25068274, 2014. ,
HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.55, issue.1, pp.33-42, 2012. ,
The French national prospective cohort of patients co-infected with HIV and HCV, ANRS CO13 HEPAVIH): Early findings, vol.10, p.20969743, 2006. ,
URL : https://hal.archives-ouvertes.fr/pasteur-01070193
AUDIT-C as a brief screen for alcohol misuse in primary care, Alcohol Clin Exp Res, vol.31, p.17451397, 2007. ,
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology, vol.43, p.16729309, 2006. ,
Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV/HCV-coinfected patients with detectable HCV-RNA. Medicine (Baltimore), vol.95, 2016. ,
Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings, Addict Abingdon Engl, vol.107, pp.1984-95, 2012. ,
Housing Status, Medical Care, and Health Outcomes Among People Living With HIV/AIDS: A Systematic Review, Am J Public Health, vol.106, pp.1-23, 2016. ,
Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting, BMC Public Health, vol.9, p.270, 2009. ,
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices, J Viral Hepat, vol.20, p.24168254, 2013. ,
Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy, J Clin Transl Hepatol, vol.4, p.28097100, 2016. ,
Epidemiology of hepatitis C virus infection, World J Gastroenterol WJG, vol.13, p.17552026, 2007. ,
Hepatitis C treatment for injection drug users: a review of the available evidence, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.49, pp.561-73, 2009. ,
Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review, Patient Prefer Adherence, vol.7, p.24204126, 2013. ,
Prevention, treatment and care of hepatitis C virus infection among people who inject drugs, Int J Drug Policy, vol.26, issue.1, pp.22-26, 2015. ,
Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV/HIV Coinfection: Action Required at the System, Provider, and Patient Levels, J Infect Dis, vol.207, p.23390301, 2013. ,
Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of directacting antivirals, Hepatol Baltim Md, vol.58, pp.1598-609, 2013. ,
Management of Hepatitis C Virus/HIV Coinfection Among People Who Use Drugs in the Era of Direct-Acting Antiviral-Based Therapy, Clin Infect Dis Off Publ Infect Dis Soc Am, vol.57, pp.118-142, 2013. ,
Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada, J Int AIDS Soc, vol.20, 2017. ,
Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes, Eur J Gastroenterol Hepatol, vol.18, p.16394797, 2006. ,
Hepatitis C treatment in drug users: perception versus evidence, Eur J Gastroenterol Hepatol, vol.18, p.16394792, 2006. ,
The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection, Int J Drug Policy, vol.18, p.17854725, 2007. ,
Drug injection cessation among HIV-infected injecting drug users, Addict Behav, vol.29, p.15236822, 2004. ,
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal, Neuroscience, vol.248, p.23624062, 2013. ,
How did a Housing First intervention improve health and social outcomes among homeless adults with mental illness in Toronto? Two-year outcomes from a randomised trial, BMJ Open, vol.6, 2016. ,
Housing First for Adults with Problematic Substance Use, J Dual Diagn, p.0, 2017. ,
Revolution in hepatitis C antiviral therapy, Br Med Bull, vol.113, p.25680808, 2015. ,
Prevention and management of treatment failure to new oral hepatitis C drugs, Expert Opin Pharmacother, vol.17, p.27149603, 2016. ,
Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis, CMAJ Open, vol.5, p.28401125, 2017. ,
HCV: the best cure possible or the best possible cure?, J Viral Hepat, vol.22, p.26135025, 2015. ,